LH

In a comparison of two Medical Services stocks, Labcorp Holdings (LH) and Danaher (DHR), both holding a Zacks Rank #2 (Buy), Labcorp emerges as the superior value option. LH has a forward P/E of 17.67 and PEG ratio of 1.85, compared to DHR's 27.42 and 2.94 respectively. LH received a Value grade of B versus DHR's C grade, making it more attractive to value investors.

Labcorp Holdings (LH), a leading healthcare diagnostics company, receives a #3 (Hold) rating on the Zacks Rank with a VGM Score of B. The company shows attractive valuation metrics with a forward P/E ratio of 16.84 and has seen three analyst upward earnings revisions in the last 60 days, with the consensus estimate increasing to $18.32 per share for fiscal 2026.

Labcorp Holdings is expanding its specialty testing business in oncology, women's health, autoimmune disease, and neurology through strategic acquisitions and partnerships. The company is leveraging AI and automation to improve margins, with operating margins expanding 70 basis points year-over-year. However, macroeconomic uncertainty, cost inflation, and changing reimbursement policies pose risks to testing volumes and profitability.

Natera announced a strategic collaboration with TransCode Therapeutics to use its Signatera MRD test for identifying eligible patients in a Phase 2a trial evaluating TTX-MC138, an investigational therapy targeting miR-10b in colorectal cancer patients. The partnership aims to accelerate patient enrollment by detecting residual cancer in patients with no detectable disease on imaging, addressing an unmet medical need in early cancer recurrence intervention.

OPKO Health announced an agreement to sell select BioReference assets to Labcorp for $722 million in cash plus up to $150 million in earnouts. The deal includes the 4Kscore Test, specialty testing operations, and over 80 patient service centers.

OPKO aims to focus on its biopharmaceutical business, while Labcorp expects $250 million in first-year revenue from the acquisition. OPK stock rose 17.5% following the announcement.

PACS Group shares jumped 6.2% to $47.75 on investor optimism ahead of Q3 2026 earnings release. The company is expected to report 75% earnings growth and 8.1% revenue growth. However, with unchanged consensus EPS estimates over the past 30 days, analysts caution that the stock may lack momentum for sustained gains without positive estimate revisions.

The global Decentralized Clinical Trials (DCT) market is valued at $8.8 billion in 2025 and is projected to reach $18.8 billion by 2030, growing at a 13.7% CAGR. Growth is driven by AI integration, wearable technologies, cloud-based platforms, and increased adoption of remote research capabilities across pharmaceutical, biotechnology, and contract research sectors.

Danaher Corporation's Biotechnology segment drove growth with 4% reported sales increase to $1.92 billion in Q2 2026, bolstered by strong China demand and consumables sales. Despite regional headwinds in Western Europe and North America, DHR expects mid-single-digit core growth in 2026. The stock trades at a premium valuation of 24.92X forward P/E versus the industry average of 16.59X and carries a Zacks Rank #3 (Hold).

GENFIT reported strong first-half 2026 financial results with €113.8 million in cash, driven by tripling royalty revenues from Ipsen's Iqirvo® (€21.1 million) and a €17 million milestone payment. The company is advancing three Phase 2 clinical trials including nangibotide and nitazoxanide for ACLF, while its NIS™ diagnostic technology achieved Medicare coverage for NASHnext®. Ipsen doubled Iqirvo's peak sales target to €1 billion for PBC, and IQVIA estimates NIS™-based products could exceed $1.5 billion in U.S. peak sales by 2033.